Luis Miguel Marín Gómez

Luis Miguel Marín Gómez

Auto-generated profile, based on publicly available information

Luis Miguel Marín Gómez

Liver Transplantation Unit, Digestive Surgery Department, Virgen del Rocio University Hospital, Seville, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in The American Journal of Surgery
Verified
Journal Article
Closed access
MGMiguel Ángel García-Ureña
Miguel Ángel García-Ureña
VRVicente Vega Ruiz
Vicente Vega Ruiz
AGAntonio Díaz Godoy
Antonio Díaz Godoy
JPJose María Báez Perea
Jose María Báez Perea
LGLuis Miguel Marín Gómez
Luis Miguel Marín Gómez
MGMiguel Ángel Velasco García
Miguel Ángel Velasco García

10 January 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
IDIrene Delgado
Irene Delgado
MCManuel Carrasco
Manuel Carrasco
ECElena Cano
Elena Cano
Rita CarmonaRita Carmona
Rita Carmona
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
ARAnabel Rojas
Anabel Rojas
The zinc finger transcription factor GATA4 controls specification and differentiation of multiple cell types during embryonic development. In mouse embryonic liver, Gata4 is expressed in the endodermal hepatic bud and in the adjacent mesenchyme of the septum transversum. Previous studies have shown that Gata4 inactivation impairs liver formation. However, whether these defects are caused by loss of Gata4 in the hepatic endoderm or in the septum transversum mesenchyme remains to be determined. In this study, we have investigated the role of mesenchymal GATA4 activity in liver formation. We have conditionally inactivated Gata4 in the septum transversum mesenchyme and its derivatives by using Cre/loxP technology. We have generated a mouse transgenic Cre line, in which expression of Cre recombinase is controlled by a previously identified distal Gata4 enhancer. Conditional inactivation of Gata4 in hepatic mesenchymal cells led to embryonic lethality around mouse embryonic stage 13.5, likely as a consequence of fetal anemia. Gata4 knockout fetal livers exhibited reduced size, advanced fibrosis, accumulation of extracellular matrix components and hepatic stellate cell (HSC) activation. Haploinsufficiency of Gata4 accelerated CCl4-induced liver fibrosis in adult mice. Moreover, Gata4 expression was dramatically reduced in advanced hepatic fibrosis and cirrhosis in humans. Conclusions: Our data demonstrate that mesenchymal GATA4 activity regulates HSC activation and inhibits the liver fibrogenic process. (Hepatology 2014;59:2358–2370)

1 May 2013 in Mitochondrion
Verified
Journal Article
Closed access
Jordi MuntanéJordi Muntané
Jordi Muntané
ARAngel J. De la Rosa
Angel J. De la Rosa
LMLuís M. Marín
Luís M. Marín
FPFrancisco J. Padillo
Francisco J. Padillo

1 October 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
GAG. Suarez Artacho
G. Suarez Artacho
LPL. Barrera Pulido
L. Barrera Pulido
JMJ.M. Alamo Martinez
J.M. Alamo Martinez
JDJ. Serrano Diez-Canedo
J. Serrano Diez-Canedo
CBC. Bernal Bellido
C. Bernal Bellido
MBMIGUEL ANGEL GOMEZ BRAVO
MIGUEL ANGEL GOMEZ BRAVO

1 September 2012 in Transplantation Proceedings
Verified
Journal Article
Closed access
LML.M. Marín-Gómez
L.M. Marín-Gómez
CBC. Bernal-Bellido
C. Bernal-Bellido
JÁJ.M. Álamo-Martínez
J.M. Álamo-Martínez
FPF.M. Porras-López
F.M. Porras-López
GSG. Suárez-Artacho
G. Suárez-Artacho
MBMIGUEL ANGEL GOMEZ BRAVO
MIGUEL ANGEL GOMEZ BRAVO

7 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJavier Padillo
Javier Padillo
GSGonzalo Suarez
Gonzalo Suarez
SPSheila Pereira
Sheila Pereira
FCFrancisco José Calero Castro
Francisco José Calero Castro
JTJose Tinoco
Jose Tinoco
MSMaría Jose Serrano
María Jose Serrano
Background. Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal blood (PV). Methods. In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by Epi-fluorescence and confocal microscopy. Results. CTC and the clusters were detected both in PV and CVC. In both samples, the CTC number per cluster was higher in patients with grade three or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated. Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than 185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant correlations were not observed in CVC analyses. Conclusions. CTC presence in PV could be an important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could be used as a diagnostic biomarker for pancreatic cancer.